arrow
A

Agnieszka Wierzbowska

multidisciplinary provincial center of traumatology and oncology nicolas copernicus in lodz
H指数:29
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL—A Case-Matched Retrospective Analysis of the Polish Adult Leukemia Group (PALG)

比较继发性急性早幼粒细胞白血病(APL)与原发APL患者的结局——波兰成人白血病组(PALG)的病例匹配回顾性分析

Cancers
IF4.4
2026-09-080
OA
Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy – a multicenter study from Polish Adult Leukemia Group

综合老年评估(CGA)量表无法有效识别适合接受强化诱导化疗的老年AML患者——波兰成人白血病小组的多中心研究

2026-02-140
OAAI
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

2025年急性髓系白血病微小残留病更新:ELN-DAVID微小残留病工作组共识文件

Blood
IF23.1
2025-12-160
OAAI
Standard Non-Intensive Chemotherapy Vs Venetoclax-Azacytidine (Ven-AZA) for Unfit AML Patients with Therapy-Related Acute Myeloid Leukaemia (t-AML)- a Retrospective Study of Polish Adult Leukemia Group (PALG)

标准非强化化疗与Venetoclax-Azacytidine(Ven-AZA)治疗不适合化疗的伴治疗相关急性髓系白血病(t-AML)患者的比较——一项波兰成人白血病组(PALG)的回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience
2024-05-210
OAAI
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
2023-12-192
OAAI
The EHA Research Roadmap: Malignant Myeloid Diseases
2021-09-013
OAAI
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
2021-05-118
OAAI